Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Detection Inks Distribution Deal with Eldan for Israel, Palestinian Territories

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Detection and Eldan today announced an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in Israel and the Palestinian territories.

Financial and other terms of the deal were not disclosed. Eldan, based in Petach Tikva, Israel, is a diagnostic distributor that is part of the Neopharm Group.

The Detect-Ready MRSA panel is CE-marked for detecting methicillin-resistant Staphylococcus aureus and methicillin-sensitive S. aureus. In a joint statement, the two companies said that the panel is the only marketed PCR-based screen proven to be able to discriminate between MRSA, MSSA, and other related bacteria.

The test kits are off-the-shelf, room temperature-stabilized and are compatible with multiple real-time PCR platforms, including the Roche LightCycler, Qiagen Rotor-Gene, and Cepheid SmartCycler.

The panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, Australia, the Netherlands, Belgium, and Luxembourg. It is in late-stage development in the US.

MDI signed distribution deals for Detect-Ready MRSA covering the Benelux region and Australia in the fall.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.